Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMeenakshi DevidasGCGunnar CarioGEGabriele Escherich

Discussion

Loading...

Member takes

Overview

Multinational cohort study shows outcomes in pediatric T-cell ALL with ABL-class fusions, indicating prognostic factors include CNS involvement.

Key Points

  • To describe the clinical characteristics and outcomes of children with T-cell ALL harboring ABL-class fusions.
  • Multinational retrospective cohort study involving 14 groups from the Ponte di Legno consortium.
  • Data collected for newly diagnosed pediatric T-ALL patients with ABL-class fusions between 1987 and 2023.
  • Assessment of clinical characteristics, treatment, and outcomes.
  • 196 children with ABL-class T-ALL analyzed.
  • 5-year event-free survival was 78.1% and overall survival was 83.6%.
  • CNS involvement was noted in 18.7% of patients, impacting prognostic outcomes.

Cite This Study

Devidas et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d034https://doi.org/10.1182/blood-2025-761
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-0012025
  2. 2Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)2025
  3. 3Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia2026
  4. 4Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL2025
  5. 5Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol2025